3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
2
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
552
Neoplasms
502
Carcinoma, Non-Small-Cell Lung
419
Prostatic Neoplasms
326
Colorectal Neoplasms
310
Lung Neoplasms
280
Neoplasm Metastasis
233
Leukemia, Myeloid, Acute
222
Ovarian Neoplasms
205
Pancreatic Neoplasms
195
Multiple Myeloma
186
Recurrence
141
Squamous Cell Carcinoma of Head and Neck
140
Brain Neoplasms
139
Stomach Neoplasms
138
Melanoma
132
Carcinoma, Hepatocellular
130
Endometrial Neoplasms
127
Glioblastoma
124
Triple Negative Breast Neoplasms
116
Precursor Cell Lymphoblastic Leukemia-Lymphoma
115
Hematologic Neoplasms
102
Head and Neck Neoplasms
100
Urinary Bladder Neoplasms
98
Carcinoma, Renal Cell
98
Lymphoma
97
Glioma
94
Sarcoma
93
Esophageal Neoplasms
90
Uterine Cervical Neoplasms
88
Interventions
pembrolizumab
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Urologic Diseases
×
90 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled